This page shows the latest Thyroid eye disease news and features for those working in and with pharma, biotech and healthcare.
First FDA-approved treatment for rare autoimmune condition. Horizon Therapeutics has won a speedy approval for its thyroid eye disease (TED) treatment Tepezza in the US. . ... We believe teprotumumab may impact underlying mechanisms of fibrosis and
thyroid eye disease (TED). ... It’s most often caused by an overactive thyroid gland (Graves’ disease), and occurs in around one in four people with that condition.
New treatment helps lessen eye bulging. Horizon Pharma shares rose strongly after it reported a positive phase 3 trial of teprotumumab for the treatment of active thyroid eye disease (TED), which ... If approved, teprotumumab would give physicians the
One study – to investigate neonatal respiratory distress syndrome – received $1.4m; one involving thyroid eye disease received $1.2m; and three more received less than $1m.
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
43% complete responses indicating the disease had disappeared entirely. ... Another of its partners, Horizon Therapeutics recently submitted to the FDA the Genmab-developed teprotumumab for the treatment of active thyroid eye disease.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
We love what we do and we think it shows.It shows in the work we do, the space we work...